BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
70.72
-3.21 (-4.34%)
Feb 19, 2026, 4:00 PM EST - Market closed
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $120.70M in the quarter ending September 30, 2025, with 4,318.01% growth. This brings the company's revenue in the last twelve months to $353.78M, up 62.46% year-over-year. In the year 2024, BridgeBio Pharma had annual revenue of $221.90M with 2,285.27% growth.
Revenue (ttm)
$353.78M
Revenue Growth
+62.46%
P/S Ratio
38.52
Revenue / Employee
$484,630
Employees
730
Market Cap
13.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | 40.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.16B |
| Genmab | 3.72B |
| BioMarin Pharmaceutical | 3.09B |
| Exelixis | 2.32B |
| Moderna | 1.94B |
| Ionis Pharmaceuticals | 966.96M |
| Madrigal Pharmaceuticals | 958.40M |
| Ascendis Pharma | 845.52M |
BBIO News
- 2 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET - GlobeNewsWire
- 7 days ago - Allspring Growth Fund Q4 2025 Fund Performers And Detractors - Seeking Alpha
- 7 days ago - BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript - Seeking Alpha
- 8 days ago - BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - GlobeNewsWire
- 11 days ago - BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection - Seeking Alpha
- 23 days ago - CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - GlobeNewsWire